What each one is
Semaglutide is a once-weekly GLP-1 receptor agonist. FDA-approved as Ozempic for type 2 diabetes and as Wegovy for weight management. Manufactured by Novo Nordisk. Half-life of approximately 7 days.
Tirzepatide is a once-weekly dual GLP-1 + GIP receptor agonist. FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for weight management. Manufactured by Eli Lilly. Half-life of approximately 5 days.
The mechanistic difference matters: GIP receptors handle a different slice of metabolic signaling than GLP-1, particularly around insulin secretion and adipose tissue function. In practice, the addition of GIP agonism produces incremental fat-loss efficacy on top of the GLP-1 effect.
The trial data
The SURMOUNT-5 head-to-head trial published 2024 was the cleanest direct comparison we have. Adults with obesity (without diabetes), randomized to maximum tolerated dose of semaglutide or tirzepatide for 72 weeks.
Mean body weight reduction: - Tirzepatide: approximately 20.2% - Semaglutide: approximately 13.7%
The gap is consistent across most subgroup analyses. Tirzepatide produces materially more weight loss in head-to-head conditions in this population. That's the headline. The nuance follows.
Side effect profile
Both peptides share the GLP-class side effect signature: nausea, constipation, diarrhea, vomiting, GERD-like symptoms, transient fatigue. The titration ramp matters more than the peptide for tolerability.
In SURMOUNT-5, gastrointestinal side effects were reported at similar rates for both compounds, with a slight edge to semaglutide for "events leading to discontinuation." In other words: tirzepatide produces more weight loss, but at a slightly higher tolerability cost in some users.
Documented less-common side effects (both): - Pancreatitis (rare, signal) - Gallbladder events (cholelithiasis, cholecystitis) - Hypoglycemia (mainly in diabetic users on insulin or sulfonylureas) - Injection site reactions - Fatigue, "ozempic face" (rapid fat loss visible in face/neck)
For tirzepatide-specific signals: increased reports of mild tachycardia and a tighter dose-response curve on GI side effects.
Use-case breakdown
"I want maximum weight loss" **Tirzepatide.** The data is consistent. If you can tolerate the titration and access the compound, it produces more loss.
"I have type 2 diabetes and need glycemic control" Both work. Tirzepatide produces marginally better A1C reduction in head-to-head data. Either is appropriate; this is a conversation with your prescribing endocrinologist who has your specific labs.
"I'm sensitive to GI side effects" Lean **semaglutide**. The slower-titration FDA-approved label and slightly milder GI signature in the available data suggest semaglutide may be the more comfortable run for users with GI sensitivity.
"I want to maintain weight loss long-term" Both require continuous administration to maintain effect. Discontinuation produces approximately 50% weight regain within 12 months in both compounds. Long-term comparisons here are still emerging.
"I want the option with more long-term data" **Semaglutide.** It's been on-market longer with more cumulative patient-years of post-market surveillance. Tirzepatide is newer but generating data quickly.
"I want the cheaper option in 2026" This shifts month-to-month based on supply chain and compounding pharmacy availability. Compounded versions of both have come and gone from the market depending on FDA shortage status. Pepdex doesn't recommend specific sources; check current legal status before purchasing.
What about retatrutide?
The next-generation triple agonist (GLP-1 + GIP + glucagon) is in late-stage trials and has produced even larger weight-loss numbers (approximately 24% at 48 weeks in phase 2). It is not yet FDA approved. The retatrutide entry on Pepdex tracks the regulatory and trial status.
What we tell users
If you are starting from a clinical decision point with a real prescribing provider, both are excellent options and the answer depends on your specific medical context. If you are researching this for a self-administered protocol, the tradeoffs above are real, and the tirzepatide page and semaglutide page on Pepdex have the documented dose ranges, side effects, and contraindications.
The detailed comparison page is at /compare/tirzepatide-vs-semaglutide.
Important reminder
Educational only. Personal dosing decisions are between you and a qualified prescribing provider.
Want the full breakdown on every peptide?
$7.99/mo unlocks the AI Coach, Personal Stack, and complete per-peptide deep sections.
Upgrade to Pepdex →